Table 2.
Projected Clinical Impact of Long-Acting Cabotegravir-Rilpivirine With Wraparound Services Compared With Oral Integrase Inhibitor–Based Antiretroviral Therapy With or Without Wraparound Services for Nonsuppressed People With HIV Experiencing Adherence Barriers
| At 3 Years | ||||
|---|---|---|---|---|
| Strategies | Viral Suppression, %a | Engagement in Care, %a | Survival, %a | Life Expectancy, y |
| CD4 count = 150 (SD, 75) cells/µL (base case) | ||||
| INSTI | 16 | 45 | 73 | 7.4 |
| INSTI/WS | 38 | 57 | 77 | 9.0 |
| CAB-RPV/WS | 44 | 58 | 79 | 9.4 |
| One-way sensitivity analyses for cohorts of PWH with different baseline CD4 counts | ||||
| CD4 count = 50 (SD, 25) cells/µL | ||||
| INSTI | 16 | 40 | 62 | 6.3 |
| INSTI/WS | 37 | 54 | 71 | 8.3 |
| CAB-RPV/WS | 43 | 56 | 74 | 8.7 |
| CD4 count = 350 (SD, 75) cells/µL | ||||
| INSTI | 16 | 46 | 81 | 9.0 |
| INSTI/WS | 38 | 59 | 83 | 10.2 |
| CAB-RPV/WS | 44 | 59 | 83 | 10.4 |
| CD4 count = 500 (SD, 75) cells/µL | ||||
| INSTI | 16 | 46 | 83 | 9.7 |
| INSTI/WS | 38 | 59 | 84 | 10.7 |
| CAB-RPV/WS | 44 | 59 | 84 | 10.8 |
Abbreviations: CAB-RPV/WS, long-acting injectable cabotegravir-rilpivirine with wraparound services; INSTI, oral integrase inhibitor–based antiretroviral therapy; INSTI/WS, oral integrase inhibitor–based antiretroviral therapy with wraparound services; PWH, people with human immunodeficiency virus; SD, standard deviation.
These percentages were calculated by dividing the number of simulated PWH who would be virologically suppressed, engaged in care, or alive at 3 years by the total number of simulated PWH at model start.